Literature DB >> 14646392

Treatment of congenital nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride in an adult patient.

Tadashi Konoshita1, Masahiro Kuroda, Takashi Kawane, Ichiro Koni, Isamu Miyamori, Yohei Tofuku, Hiroshi Mabuchi, Ryoyu Takeda.   

Abstract

AIM: The effects of treatment with hydrochlorothiazide (HCTZ) combined with amiloride were elucidated and compared to HCTZ treatment alone and combined with acemetacin or triamterene in a Japanese adult patient with congenital nephrogenic diabetes insipidus.
METHODS: The study was divided into seven periods: (1) HCTZ and acemetacin; (2) control period; (3) HCTZ; (4) a second control period; (5) HCTZ and amiloride; (6) a third control period, and (7) HCTZ and triamterene. Fluid intake, urine volume, urinary Na, K, creatinine, and osmolality and serum Na, K, Cl, CO2, and osmolality were measured, and free water clearance and proximal and distal tubular Na reabsorption rates were calculated.
RESULTS: Without drug administration, the urine volume was about 8,000 ml/day. The urine volume was reduced to about 6,000 ml/day with HCTZ. A further urine volume reduction to about 5,000 ml/day was obtained with the second drug administration, and the effects were similar among the three regimens. Serum and urinary osmolality and free water clearance were also similar among the three combinations, whereas the urinary potassium excretion was the least, and the serum potassium concentration was the highest with HCTZ plus amiloride. Besides, no alkalosis was observed only with this combination.
CONCLUSION: HCTZ plus amiloride may be superior to HCTZ plus acemetacin and HCTZ plus triamterene in preventing hyperkaliuria, hypokalemia, and metabolic alkalosis. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14646392     DOI: 10.1159/000075241

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  5 in total

1.  Identification of a Novel Arginine Vasopressin Receptor 2 Mutation (p.V183M) in a Chinese Family with Nephrogenic Diabetes Insipidus.

Authors:  Ji-Shi Liu; Hao Huang; Jie-Yuan Jin; Ran Du; Chen-Yu Wang; Liang-Liang Fan
Journal:  Mol Syndromol       Date:  2020-03-28

2.  EGF Receptor Inhibition by Erlotinib Increases Aquaporin 2-Mediated Renal Water Reabsorption.

Authors:  Pui W Cheung; Naohiro Nomura; Anil V Nair; Nutthapoom Pathomthongtaweechai; Lars Ueberdiek; Hua A Jenny Lu; Dennis Brown; Richard Bouley
Journal:  J Am Soc Nephrol       Date:  2016-03-09       Impact factor: 10.121

3.  Nrf2 activation protects against lithium-induced nephrogenic diabetes insipidus.

Authors:  Soma Jobbagy; Dario A Vitturi; Sonia R Salvatore; Maria F Pires; Pascal Rowart; David R Emlet; Mark Ross; Scott Hahn; Claudette St Croix; Stacy G Wendell; Arohan R Subramanya; Adam C Straub; Roderick J Tan; Francisco J Schopfer
Journal:  JCI Insight       Date:  2020-01-16

4.  A Rare Case of Congenital Diabetes Insipidus.

Authors:  Tanvi Rege; Srujana Polsani; Belinda Jim
Journal:  Front Med (Lausanne)       Date:  2015-07-07

5.  Congenital Nephrogenic Diabetes Insipidus Presented With Bilateral Hydronephrosis and Urinary Infection: A Case Report.

Authors:  Kewen Zheng; Yi Xie; Hanzhong Li
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.